IP Library Granted Patent US 8,512,730
Granted Patent B2
US 8,512,730 · App. 11/448,701 · Granted Aug 20, 2013

Methods of tissue repair and compositions therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,512,730
App. No.
11/448,701
Granted
Aug 20, 2013
Kind
B2
Abstract

The present application discloses matrix compositions to support the repair of tissue defects such as an injury to tendon tissue, ligament tissue, vascular tissue, dermal tissue, or muscle tissue. A matrix described herein comprises a polyester polymer entangled with a polysaccharide polymer. Also disclosed are methods of preparing a matrix, and methods of using a matrix in the repair of tissue. In certain configurations, a matrix can comprise a polyester cross-linked with a polysaccharide, which can be an oxidized polysaccharide. In some configurations, a matrix can further comprise one or more additional components, such as a growth factor or an anti-infective agent. In some configurations, a matrix can be a viscous fluid or a paste, while in other configurations a matrix can be comprised by a solid such as a plug, a granule or a membrane.

Claims (17)

1. A method of promoting tissue growth at a tissue site in need of tissue growth in a mammal in need thereof, the method comprising injecting an injectable tissue matrix composition at the site, wherein the injectable matrix composition comprises polyester polymers entangled with hyaluronic acid polymers by a process comprising the steps of: (i) dissolving the polyester polymers in an organic solvent; (ii) blending the polyester polymers with hyaluronic acid polymers contained in an aqueous medium to form an emulsified mixture; and (iii) pouring the emulsified mixture of the two polymers into a mold, (iv) successively removing the organic solvent and water from the mold to form a solid matrix comprising the polyester polymers entangled with the hyaluronic acid polymers; (v) granulating the solid matrix to form matrix granules; and (vi) combining the matrix granules with an aqueous liquid solution comprising hyaluronic acid to form a paste or a viscous liquid capable of injection at the tissue site.

2. The method of claim 1 , wherein the matrix composition comprises a paste.

3. The method of claim 1 , wherein the matrix composition comprises a viscous liquid.

4. The method of claim 1 , wherein the mammal is a human in need of treatment.

5. The method of claim 1 , wherein the site in need of tissue growth comprises bone and periosteal tissue.

6. The method of claim 1 , wherein the tissue growth comprises facial contour augmentation.

7. The method of claim 1 , wherein the matrix further comprises at least one therapeutic agent.

8. The method of claim 7 , wherein the at least one therapeutic agent is selected from the group consisting of an anti-infective agent, a pain medication, an analgesic, an anti-inflammatory agent, and an immunosuppressive agent.

9. The method of claim 1 , wherein the site in need of tissue growth comprises bone and a periodontal ligament.

10. The method of claim 1 , wherein the site in need of tissue growth comprises bone and cartilage.

11. The method of claim 1 , wherein the site in need of tissue growth comprises bone and hyaline cartilage.

12. The method of claim 11 wherein the hyaline cartilage is costal cartilage.

13. The method of claim 1 , wherein the site in need of tissue growth comprises bone and fibrous cartilage.

14. The method of claim 13 wherein the fibrous cartilage is meniscus cartilage.

15. The method of claim 1 , wherein the polyester polymers and hyaluronic acid polymers are combined at a weight ratio of polyester polymers to hyaluronic polymers of between 9:1 and 1:9.

16. The method of claim 1 , wherein the matrix composition is characterized by (i) retention of pore structure and shape when hydrated, and (ii) the ability to support the growth of cells in vivo or ex vivo.

17. The method of claim 1 , wherein the site in need of tissue growth is selected from the group consisting of bone tissue, cartilage tissue, tendon tissue, ligament tissue, vascular tissue, dermal tissue, periodontal tissue, intervertebral disc tissue, hyaline cartilage, fibrous cartilage, elastic cartilage, a nerve tunnel or a combination thereof.

Assignments (8)
SECURITY INTEREST Recorded Sep 18, 2025
From: ISTO TECHNOLOGIES II, LLC; ADVANCED BIOLOGICS LLC,; ARTERIOCYTE MEDICAL SYSTEMS, INC.; THERACELL, LLC
To: GOLUB CAPITAL MARKETS LLC
Reel/Frame 072300/0216 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2025
From: BARINGS FINANCE LLC, AS COLLATERAL AGENT
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
Reel/Frame 072274/0408 →
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2023
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 065269/0604 →
SECURITY INTEREST Recorded Oct 18, 2023
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
To: BARINGS FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065271/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2018
From: ISTO TECHNOLOGIES, INC.
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 045478/0013 →
SECURITY INTEREST Recorded Jun 15, 2017
From: ISTO TECHNOLOGIES II, LLC
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 042727/0459 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2016
From: MIDCAP FUNDING XVIII TRUST, AS SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL SBIC, LP
To: ISTO TECHNOLOGIES, INC.
Reel/Frame 038903/0645 →
SECURITY INTEREST Recorded Jan 23, 2015
From: ISTO TECHNOLOGIES, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 034805/0001 →